Mohamed‐Eslam F. Mohamed
AbbVie (United States)(US)
Publications by Year
Research Areas
Rheumatoid Arthritis Research and Therapies, Chronic Lymphocytic Leukemia Research, Pharmacogenetics and Drug Metabolism, Inflammatory Bowel Disease, Autoimmune and Inflammatory Disorders Research
Most-Cited Works
- → Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial(2018)426 cited
- → Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease(2023)385 cited
- → Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial(2019)348 cited
- → Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease(2020)303 cited
- → Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate‐Naive Patients With Moderately‐to‐Severely Active Rheumatoid Arthritis (SELECT‐EARLY): A Multicenter, Multi‐Country, Randomized, Double‐Blind, Active Comparator–Controlled Trial(2020)218 cited
- → Upadacitinib: Mechanism of action, clinical, and translational science(2023)125 cited
- → Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis(2016)115 cited
- → Genetic and nongenetic factors associated with warfarin doserequirements in Egyptian patients(2011)101 cited
- → Effects of Herbal Supplements on Drug Glucuronidation. Review of Clinical, Animal, andIn VitroStudies(2010)87 cited
- → Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials(2017)82 cited